On the stock market since 1980, it operates in the world of health and science. It has 136 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $166.4M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 1,223% — still a thick cushion, though costs have been eating into it lately.
There is $191.4M in the vault; even if every debt were paid off, $166.4M would remain.
The average analyst price target is $17.67 — 196% above today’s price.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 20/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 26/100.
The growth engine is running at low revs right now. Report-card grade: 30/100.
On our five-subject report card, ABEO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ABEO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (26/100) says the stock isn’t cheap.